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Abstract: Trk receptor tyrosine kinases are required for signal transduction initiated by neurotrophins leading to cell pro-
liferation, differentiation, survival and death. Alterations in Trk kinase activity have been linked to various diseases. To 
address the need for cell-based assays for screening and studying the selectivity of Trk kinase modulators, we developed 
high-throughput cell-based assays for Trk receptor kinases using nuclear factor of activated T-cells (NFAT) beta-
lactamase reporter lines stably expressing full length human Trk kinases. These assays were functionally validated with 
cognate neurotrophin(s), inhibitors and TRK RNAi oligos and demonstrated for their utility in identifying potent and se-
lective modulators of Trk receptor kinases. 
INTRODUCTION 
  Neurotrophin signaling plays an essential role in neuronal 
and non-neuronal cell proliferation, differentiation, survival 
and death. Alterations in neurotrophin signaling have been 
linked to neurodegenerative disorders such as Alzheimer’s 
disease, psychiatric disorders such as depression, as well as 
various cancers including neuroblastoma [1, 2]. Neurotro-
phins are a family of growth factors including nerve growth 
factor (NGF), brain-derived neurotrophic factor (BNDF), 
neurotrophin 3 (NT-3) and neurotrophin 4 (NT-4) [1]. Each 
neurotrophin can bind and activate two types of cell surface 
receptors – the Trk family receptor tyrosine kinases (TrkA, 
TrkB and TrkC) and the p75 neurotrophin receptor (p75
NTR). 
p75
NTR binds all neurotrophins with a similar affinity, 
whereas the Trk receptors are selective for different neu-
rotrophins. NGF binds preferentially to TrkA; BDNF and 
NT-4 to TrkB; NT-3 preferably to TrkC receptor. Unlike 
other neurotrophins, NT-3 is promiscuous and can also bind 
TrkA and TrkB with lower affinity at least in certain cell 
types [3]. The binding of neurotrophins to their cognate Trk 
receptor leads to Trk dimerization and autophosphorylation. 
The phosphorylated receptors then recruit and increase the 
phosphorylation of phospholipase C- (PLC-), Src and Shc, 
which leads to the activation of PI3K, ERK and PKC/Ca
2+
pathways. These events in turn result in the activation of 
transcription factors such as cyclic AMP-response element 
binding protein (CREB) and nuclear factor of activated T-
cells (NFAT) leading to downstream gene expression [4]. 
The importance of Trks in neurotrophin signaling has made 
Trk kinases candidate targets for several therapeutic areas. 
Constitutively active oncogenic forms of TrkA and TrkC 
have been found in patients with neuroblastoma and leuke-
mia [5, 6]. There are currently few specific Trk inhibitors 
available for therapy. Similar to CEP701, K252a, an indole 
carbazol compound of microbial origin, has been widely 
used as a Trk inhibitor [7]. It also inhibits many other 
kinases including mixed-lineage kinase 3 (MLK3) [8].  
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  The lack of specific Trk inhibitors is partially due to the 
lack of robust cell-based assay tools for high-throughput 
screening. The most commonly used assays for Trk activity 
include low-throughput receptor autophosphorylation analy-
sis by western blotting [9] and luciferase-based reporter as-
says for TrkA and B [10]. Here, we described the develop-
ment of cell based assays for all three Trk kinases applicable 
to high-throughput screening. Human full length TrkA, B 
and C cDNAs were each stably integrated into a NFAT beta-
lactamase (NFAT-bla) reporter line. Single clones for each 
Trk were isolated by fluorescence-activated cell sorting 
(FACS) based on their response to neurotrophins. Each cell 
line was validated with the cognate ligand(s), known inhibi-
tors and TRK specific RNAi oligos. The selectivity and ro-
bustness of our reporter assays for Trk kinases indicate that 
these assays are suitable for high-throughput screening of 
Trk modulators as well as determining the selectivity of 
compounds against three Trk kinases. 
PRINCIPLE OF ASSAY DESIGN 
  Expression vectors carrying full length human TrkA, 
TrkB or TrkC were each stably transfected into NFAT-bla
CHO-K1 reporter line characterized previously (Fig. 1). Sin-
gle clone for each Trk was isolated after FACS sorting. 
Ligand binding to its cognate receptor (NGF for TrkA, 
BDNF for TrkB and NT-3 for TrkC) leads to the activation 
of PLC-/PKC/Ca
2+ pathway, which in turn activates tran-
scription factor NFAT. Activated NFAT translocates to the 
nucleus and bind to its DNA response elements driving the 
expression of downstream reporter gene, in this case, beta-
lactamase (Fig. 1). Beta-lactamase activity can be detected 
by adding its substrate, CCF4-AM, directly onto cells [11]. 
In the absence of neurotrophins, the pathway is not active 
therefore there is little beta-lactamase activity. When cells 
are loaded with CCF4-AM and are excited at 406 nm, the 
substrate emits at around 530 nm. When cells are stimulated 
with neurotrophin, the pathway is activated, leading to the 
beta-lactamase reporter activation. The loaded substrate is 
then cleaved by beta-lactamase, disrupting the fluorescence 
resonance energy transfer (FRET) and resulting in emission 
at 460 nm with excitation at 406 nm. 28 Current Chemical Genomics, 2008, Volume 1  Wang et al. 
Fig. (1). Diagram of the cell line design for Trk receptor kinases.
METHODS 
Generation of Stable Cell Clones 
  Full length human TRKA, TRKB and TRKC cDNAs 
were synthesized by Blue Heron Biotechnology (Bothell, 
MA) according to the sequences of NM_002529 for TRKA, 
NM_006180 for TRKB and NM_002530 for TRKC, and 
cloned into pcDNA6.2/V5-DEST (Invitrogen, Carlsbad, CA) 
via Gateway™ LR reaction.  
  NFAT beta-lactamase reporter line NFAT-bla CHO-K1 
cells (Invitrogen, Carlsbad, CA, catalog number K1078) 
were transfected using Lipofectamine™ LTX transfection 
reagent (Invitrogen, Carlsbad, CA) with pcDNA6-TRKA, 
pcDNA6-TRKB and pcDNA6-TRKC and selected for blas-
ticidin-resistance. Blasticidin-resistant TrkA transfected cells 
were stimulated with NGF (Invitrogen, catalog number 
13257-019), TrkB transfected cells with BDNF (Invitrogen, 
catalog number PHC7074) and TrkC transfected cells with 
NT-3 (Invitrogen, catalog number PHC7034) for 5 hours 
before neurotrophin stimulated beta-lactamase expressing 
cells were collected by FACS as single cells onto 96-well 
plates. The survived clones that responded to the respective 
ligand were selected and expanded. The clone with the best 
response to each ligand was further tested in a 384-well for-
mat for the dose response of neurotrophins and inhibitors 
and in a 96-well format for RNAi knock-down. 
Neurotrophin Stimulation and 384-Well Beta-Lactamase 
Assay Protocol 
  Cells in a sub-confluency state (or cryopreserved cells) 
were resuspended in Assay Medium (DMEM with Glu-
taMAX
TM (Invitrogen, catalog number 10569) supplemented 
with 0.1% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES, 
100 U/mL Penicillin and 100  g/mL Streptomycin) and 
plated in a 384-well assay plate (Corning, Lowell, MA, cata-
log number 3712) at 10,000 cells (32 L) per well. 32 L of 
Assay Medium without cells were plated in Cell-free Control 
wells on the same plate. 4  L 1% DMSO was added to each 
well to reach final DMSO concentration of 0.1% to mimic 
the screening situation where compounds dissolved in 
DMSO are added to test wells. Cells were then stimulated 
with 4  L/well 10 x ligands (NGF, BDNF, NT-4 (Invitrogen, 
catalog number PHC7024), NT-3 or Thapsigargin (Sigma, 
St. Louis, MO)) over the indicated concentration range (1 
pM ~ 50000 pM) for 5 hours before adding 8  L/well 6X 
LiveBLAzer
TM-FRET B/G Substrate mixture (Invitrogen, 
catalog number K1096) for 2 hours. Fluorescence intensity 
at excitation 406 nm and emission 460 nm and 530 nm were 
obtained using Tecan Safire
2 fluorescence plate reader (Te-
can, Durham, NC) (Table 1). After subtracting the average 
fluorescence intensity from the Cell-free Control wells, the 
460nm/530nm emission ratio was calculated. Response Ra-
tio is a measurement of the assay window and is calculated 
as the 460nm/530nm Emission Ratio of the stimulated wells 
divided by the 460nm/530nm Emission Ratio of the unstimu-
lated wells. Response Ratios were plotted against test ligand 
concentrations in log scale and then analyzed using Prism 
software (GraphPad Software, Inc. San Diego, CA). Sigmoi-
dal dose-response equation with varying slope was used to 
fit the data and generate EC50 values. Z’-factor values were 
calculated as: Z’-factor = 1 - [(3 x stdevunstim + 3 x stdevmax-
stim) / (avgmaxstim – avgunstim)]. 
Inhibitor Treatment 
  Cells were seeded into a 384-well assay plate at 10,000 
cells/well as described above and treated for 30 minutes with 
4  L of AG879 (EMD, San Diego, CA, catalog number 
658460), or GW441756 (Tocris Bioscience, Ellisville, MO, 
catalog number 2238) or K252a (Invitrogen, catalog number 
Table 1.  Beta-Lactamase Assay Protocol for Trk-NFAT-bla CHO-K1 Cells in 384-Well Format 
Step Parameter  Value  Description 
1 Cells  32  L Trk-NFAT-bla CHO-K1 cells, 10,000 cells/well 
2 DMSO  or  Compound  4  L  10 X compound solution or 1% DMSO 
3 Neurotrophin  4  L  10 X Neurotrophin 
4 Incubation  5 hrs  37°C, 5% CO2
5 Substrate  8  L  6 X CCF4-AM  
6 Incubation  2 hrs  Room Temp. 
7 Detection  fluorescence  Tecan  Safire
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PHZ1131), each at 10 x final concentrations. Cells were then 
stimulated with 4  L of neurotrophins at 10 x EC80 concen-
trations (EC80 concentrations are: NGF, 0.77 nM; BDNF, 1 
nM; NT-3, 0.72 nM; Thapsigargin, 8 nM) for 5 hours before 
beta-lactamase assay was performed as described above. 
RNAi Experiment 
  Cells were plated in 96-well assay plates (Corning, cata-
log number 3603) at 6,000 cells/well in 100  L growth me-
dium (DMEM containing 10% dialyzed FBS, 0.1 mM 
NEAA and 25 mM HEPES), and incubated in 37°C, 5% CO2
incubator overnight. Next morning, Stealth™ RNAi (Invi-
trogen, catalog number 10620318) and Lipofectamine
TM 
RNAiMAX (Invitrogen, catalog number 13778) complexes 
were prepared according to the manufacturer’s protocol and 
added to the wells (50 nM RNAi oligos and 1 L RNAi-
MAX/well). RNAi oligo targeting for beta-lactamase was 
used as the positive control and a random-sequenced oligo 
with 48% GC content (Med GC) as the negative control. A 
set of 2 oligos for each Trk was used:  
TRKA1 (ACAUCAUCGAGAACCCACAAUACUU) 
TRKA2 (ACGCUGCUCCUUGUGCUCAACAAAU) 
TRKB1 (UGGUAAUGCUGUUUCUGCUUAAGUU) 
TRKB2 (ACACCACGAACAGAAGUAAUGAAAU) 
TRKC1 (GCCAAGUGUAGUUUCUGGCGGAUUU) 
TRKC2 (CCAGACCAAUCUGAACUGGACCAAU) 
  Cells were incubated with RNAi oligos at 37°C for 32 
hours, followed by a medium change. Cells were incubated 
in Assay Medium at 37ºC for 16 hours and then stimulated 
with respective ligands (NGF, 0.77 nM; BDNF, 1 nM; NT-3, 
0.72 nM and Thapsigargin, 30 nM) for 5 hours before beta-
lactamase assay was performed as described above. 
RESULTS AND DISCUSSION 
Assay Development and Validation 
  For the purpose of developing cell-based assays for each 
Trk kinase, we generated stable clones of NFAT-bla CHO-
K1 expressing full length human TrkA, TrkB or TrkC as 
described in Methods. Each clone was validated for the dose 
response to NGF, BDNF, NT-3 and NT-4 (Fig. 2, Table 2). 
TrkA-NFAT-bla CHO-K1 cells responded well to NGF with 
a maximum response ratio of 5.5 fold (Z’ factor of 0.75) and 
an EC50 of 0.044 nM, consistent with previously published 
results [12]. TrkA-NFAT-bla CHO-K1 cells showed a 3-fold 
response over baseline to NT-3 with an EC50 around 16 nM, 
suggesting that NT-3 binds TrkA with a lower affinity than 
Fig. (2). Neurotrophin dose responses of TrkA, TrkB, TrkC and parental NFAT-bla CHO-K1 cell lines. TrkA-NFAT-bla CHO-K1 
(A), TrkB-NFAT-bla CHO-K1 (B), TrkC-NFAT-bla CHO-K1 (C), and parental NFAT-bla CHO-K1 (D) cells were stimulated with NGF 
( ), BDNF ( ), NT-4 (), NT-3 ( ) and Thapsigargin ( , parental cells only) over the indicated concentration range in the presence of 
0.1% DMSO for 5 hours before beta-lactamase assay was performed as described in Methods. Response Ratios were plotted for the indicated 
concentrations of each ligand (n=5 for each data point).  
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NGF [13]. BDNF and NT-4 had a minimal effect on TrkA-
NFAT-bla CHO-K1 cells, but significantly stimulated beta-
lactamase reporter activity in TrkB-NFAT-bla CHO-K1 cells 
with a maximum response ratio of 14 (Z’ value of 0.82) and 
an EC50 of 0.39 nM for BDNF and a maximum response 
ratio of 13 (Z’ value of 0.8) and an EC50 of 3.5 nM for NT-4 
(Fig. 2B). TrkB-NFAT-bla CHO-K1 cells also responded to 
NT-3 with a maximum response ratio of 13 and an EC50 of 
2.5 nM, but did not respond at all to NGF, which is in 
agreement with previous findings [13]. TrkC-NFAT-bla
CHO-K1 cells responded to TrkC preferred ligand NT-3 
with a maximum response ratio of 8.5 (Z’ value of 0.9) and 
an EC50 of 0.093 nM (Fig. 2C). TrkC-NFAT-bla CHO-K1 
cells responded to BDNF only at the highest concentration 
(50 nM) tested and did not show any response to NGF and 
NT-4. All three cell lines responded to thapsigargin treat-
ment with a similar EC50 (data not shown) to that of the pa-
rental NFAT-bla CHO-K1 cells (Fig. 2D). Taken together, 
TrkA-NFAT-bla CHO-K1 cells specifically responded to 
TrkA preferred neurotrophin, NGF, TrkB-NFAT-bla CHO-
K1 cells to BDNF, NT-3 and NT-4, and TrkC-NFAT-bla
CHO-K1 cells to TrkC ligand NT-3. The fact that NT-3 gen-
erated dose responses in both TrkC and TrkB cells with a 10 
fold less EC50 in TrkC cells confirms that NT-3 binds to both 
TrkC and B with TrkC being the preferred receptor. The fact 
that CHO cells lack p75
NTR expression [14] and the parental 
NFAT-bla CHO-K1 cells do not respond to neurotrophins 
(Fig. 2D) suggests that the effect we observed for each neu-
rotrophin was mediated by the engineered Trk receptor. Our 
results confirmed differential affinity and rank order potency 
of each neurotrophin to Trk receptors as reported in the lit-
erature, which suggests that these cell-based reporter assays 
for Trk kinases can be used for studying the potency and 
selectivity of Trk modulators. 
Inhibitor Activities 
  We further validated these assays with a commonly used 
Trk kinase inhibitor, K252a. Dose response experiment 
showed K252a inhibited NGF-induced beta-lactamase activ-
ity in TrkA-NFAT-bla CHO-K1 cells (Fig. 3A), BDNF-
induced beta-lactamase activity in TrkB-NFAT-bla CHO-K1 
cells (Fig. 3B) and NT-3 induced TrkC-NFAT-bla CHO-K1 
cells (Fig. 3C) with low nano-molar IC50 values (Table 3), 
which are in accordance with literature values using various 
types of assays [7, 15, 16]. Interestingly, K252a had a partial 
inhibitory effect on Thapsgargin induced reporter activity in 
all three cell lines at the highest concentration tested (Fig. 3,
Table  3). AG879, also known as an EGFR family kinase 
inhibitor [17], has been reported in the literature to inhibit 
NGF induced TrkA autophosphorylation and downstream 
PLC- phosphorylation in micro-molar concentrations [18]. 
When tested in our reporter assays, AG879 inhibited all three 
Trk-mediated NFAT activation with an IC50 around 1 M
(Table  3). Interestingly, this compounds inhibited Thapsi-
gargin-induced NFAT reporter activity with much lower 
IC50s, suggesting that AG879 affects other targets than Trks. 
GW441756, a potent TrkA inhibitor in a biochemical assay 
[19], also inhibited all three Trk kinases induced NFAT-bla
reporter activity with an IC50 value of 0.23 M for TrkA, 
0.14 M for TrkB and 0.46 M for TrkC. It also affected 
Thapsigargin-induced NFAT reporter activity, but only at 
much higher concentrations (Fig. 3, Table 3). These data 
suggest that GW441756 is a more potent and selective Trk 
inhibitor than AG879. Our data provides first evidence that 
GW441756 is a potent inhibitor for all three Trk receptor 
kinases. This inhibitor experiment demonstrated how one 
can use these three cell assays to identify compounds based 
on both potency and selectivity. 
RNAi Validation 
  To further demonstrate the specificity of each assay, we 
examined the effect of Trk specific RNAi oligos on neu-
rotrophin-induced NFAT-bla reporter activity. We also de-
termined the specificity of each oligo by examining the ef-
fect of the oligos on thapsigargin-induced reporter activity. 
Cells were treated with Stealth™ Select RNAi oligos and 
stimulated with neurotrophins as described in Methods. Beta-
lactamase gene-specific RNAi (b-lac) was used as a positive 
control and showed complete inhibition of neurotrophin-
induced reporter activity in all three cell lines (Fig. 4). RNAi 
oligo with 48% GC content (Med GC) was used as a nega-
tive control and had no inhibitory effect in any of the three 
assays. Treatment with two TrkA RNAi oligos significantly 
knocked down NGF induced beta-lactamase activity in TrkA 
expressing cells (Fig. 4A) and had little effect on BDNF in-
duced beta-lactamase activity in TrkB cells (Fig. 4B) and 
NT-3 induced in TrkC cells (Fig. 4C). Treatment with the 
two TrkB oligos completely inhibited BDNF induced re-
porter activation in TrkB cells (Fig. 4B) and had minimal 
effect on the TrkA and TrkC cells induced by NGF and NT-
3 respectively (Fig. 4A and C). Finally, treatment with the 
two TrkC oligos completely knocked down NT-3 induced 
beta-lactamase reporter activity in TrkC cells and had mini-
mal inhibitory effect on TrkA and TrkB cells (Fig. 4C). 
Longer incubation (72 hour) with these RNAi oligos gave a 
similar inhibitory pattern (data not shown). No cytotoxicity 
effect was observed with any of the RNAi oligos used even 
after 72 hour incubation. 
Table 2.  EC50 Values of Neurotrophins in the Three Trk Assays 
Neurotrophins (nM)  TrkA-NFAT-bla CHO-K1  TrkB-NFAT-bla CHO-K1  TrkC-NFAT-bla CHO-K1 
NGF 2.5s  0.04   >50  >50 
BDNF  >50 0.39 28* 
NT-4  >50 3.5 >50 
NT-3 16*  2.5  0.09 
*Values may not be accurate as the curves did not reach saturation. Cellular Assays for High-Throughput Screening  Current Chemical Genomics, 2008, Volume 1    31
Fig. (3). Inhibition of neurotrophin-induced beta-lactamase reporter activity in the cognate Trk receptor expressing cells. Cells were pre-
treated with indicated concentrations of K252a (), or AG879 () and GW441756 () and then stimulated with NGF (TrkA cells, A), 
BDNF (TrkB cells, B), or NT-3 (TrkC cells, C), or Thapsgargin for all three cell lines for 5 hours before beta-lactamase assay was performed 
as described in Methods. Response Ratios were plotted for the indicated concentrations of each compounds (n=3 for each data point).  
Table 3.  IC50 Values (in nM) of Inhibitors in the Three Trk Assays 
TrkA TrkB TrkC 
NGF Thaps  BDNF  Thaps NT-3 Thaps 
K252a  13 570* 11  >1000  30 500* 
AG879  1326  112  1011 51 1308  231 
GW44176  231 2831* 141 8205* 460 8970* 
*Values may not be accurate as the curves did not reach saturation. 
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Fig. (4). Effects of various RNAi oligos on neurotrophin-induced beta-lactamase reporter activity. Cells were incubated with indicated RNAi 
oligos for 32 hrs, followed by a medium change and additional 16 hour-incubation. Cells were then stimulated with respective ligands (NGF 
for TrkA cells, A; BDNF for TrkB cells, B; NT-3 for TrkC cells, C) for 5 hours before beta-lactamase assay was performed as described in 
Methods. Response Ratios were plotted for each RNAi oligo (n=3 for each data point). Unstim: untransfected cells were left unstimulated
with ligands; Mock: cells were treated with transfection reagent (no RNAi oligo) and stimulated with ligands.  
Fig. (5). Effects of various RNAi oligos on thapsigargin-induced beta-lactamase reporter activity. TrkA-NFAT-bla CHO-K1 (A), TrkB-
NFAT-bla CHO-K1 (B) and TrkC-NFAT-bla CHO-K1 (C) cells were incubated with indicated RNAi oligos for 32 hrs, followed by a me-
dium change and additional 16 hour-incubation. Cells were then stimulated with thapsigargin for 5 hours before beta-lactamase assay was 
performed as described in Methods. Response Ratios were plotted for each RNAi oligo (n=3 for each data point). Unstim: untransfected cells 
were left unstimulated with ligands; Mock: cells were treated with transfection reagent (no RNAi oligo) and stimulated with thapsigargin.
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To further address the specificity of these RNAi oligos, 
we examined the effect of these oligos on thapsigargin-
induced NFAT-bla reporter activity. Thapsigargin works 
downstream of the Trk receptors by directly increasing intra-
cellular Ca
2+ concentration leading to the activation of NFAT 
independent of Trk activity. Accordingly, specific Trk RNAi 
oligos should not knockdown thapsigargin induced reporter 
activity. Indeed, the two TrkA, TRKC2 and TRKB1 RNAi 
oligos did not inhibit thapsigargin effect in all three cell lines 
(Fig. 5). TRKB2 oligo and TRKC1 to a less extent, however, 
had about 50% inhibitory effect in all three cell lines stimu-
lated with thapsigargin, suggesting that TRKB2 and TRKC1 
may have effects on other targets that contribute to thapsi-
gargin induced-signaling.  
CONCLUSIONS  
  In conclusion, we have developed NFAT reporter assays 
that can be used for high-throughput screening for modula-
tors of Trk receptor tyrosine kinases. Taking the advantages 
of the beta-lactamase reporter which allows for a ratiometric 
and sensitive read-out, these assays are an improvement over 
previously described luciferase-based assays [10], which 
were shown robust in a 96-well format. Our assays are easy 
to set up, can be miniaturized to a 384-well format and take 
less than one working day to run. Most importantly, our as-
says are selective and robust with Z’ factors great than 0.7, 
pico-molar detection sensitivity and large assay windows (5 
to 14 folds). The selectivity and specificity of these assays 
were demonstrated by the EC50 results of the four neurotro-
phins and receptor RNAi knockdown experiments. The 
K252a, AG879 and GW441576 inhibitor study demonstrated 
the utility of these cell assays for determining compound 
potency and selectivity and for compound library screening 
against TrkA, TrkB and TrkC. 
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